Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients
The CALGB 8461 trial, sponsored by the Alliance for Clinical Trials in Oncology, aims to enhance the understanding of cytogenetic profiles in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). Given the increasing focus on personalized medicine, this study could provide valuable insights that may influence treatment selection and improve patient outcomes. The trial's findings could have significant implications for the development of targeted therapies and companion diagnostics in the hematological oncology market, which is projected to grow substantially. The competitive landscape includes established players in the oncology space, necessitating a thorough diligence process to assess potential partnerships or acquisitions based on the trial's outcomes.
Indication: Acute Leukemia
Modality: gene therapy
Target: Chromosomal abnormalities in acute leukemia and multiple myeloma
Sponsor: Alliance for Clinical Trials in Oncology
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Chromosomal abnormalities in acute leukemia and multiple myeloma
View original source fields
Condition raw: Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Condition normalized: Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Chromosomal abnormalities in acute leukemia and multiple myeloma
Target normalized: Chromosomal abnormalities in acute leukemia and multiple myeloma